Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB

Página do item simplificado
dc.contributor.authorAspler, Anne
dc.contributor.authorLong, Richard
dc.contributor.authorTrajman, Anete
dc.contributor.authorDion, Marie-Josée
dc.contributor.authorKhan, Kamran
dc.contributor.authorSchwartzman, Kevin
dc.contributor.authorMenzies, Dick
dc.date.accessioned2024-12-09T18:21:34Z
dc.date.available2024-12-09T18:21:34Z
dc.date.issued2010
dc.description.abstractRationale Treatment for latent tuberculosis infection with isoniazid for 9 months (9INH) has poor completion and serious adverse events, while treatment for 4 months with daily rifampin (4RIF) has significantly higher completion and fewer adverse events. Objectives To compare the health system costs of 4RIF and 9INH. Methods In a randomised trial conducted in five Canadian centres, one Brazilian and one Saudi Arabian centre, consenting subjects were randomised to receive 4RIF or 9INH. Health system costs were estimated from healthcare utilisation including scheduled and unscheduled visits, investigations and drugs. All activities for all subjects were evaluated using financial information from 2007 from the Montreal Chest Institute. Costs were expressed in Canadian dollars. Results Total health system cost per patient allocated to 4RIF was $854 compared with $970 for 9INH (p<0.0001). The average cost per patient for the 328 of 420 (78%) who completed 4RIF therapy was $1094 compared with $1625 for the 254 of 427 (60%) completing 9INH (p<0.0001). Costs were modestly increased in patients with minor intolerance and substantially increased if the treating physician stopped treatment because of possible adverse events. Total costs related to management of adverse events with 9INH were $48 142 compared with $25 684 for 4RIF (p1⁄40.008). Using these data, incremental cost- effectiveness analyses showed that 4RIF would be cost saving and prevent more cases within 2 years if efficacy exceeded 74%, and cost saving if efficacy exceeded 65%. Conclusions The 4RIF regimen was significantly cheaper per patient completing treatment because of better completion and fewer adverse events. RCT registration number NCT00170209.
dc.identifier.citationAspler A, Long R, Trajman A, Dion MJ, Khan K, Schwartzman K, Menzies D. Impact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB. Thorax. 2010 Jul;65(7):582-7. doi: 10.1136/thx.2009.125054.
dc.identifier.otherDOI: 10.1136/thx.2009.125054
dc.identifier.urihttps://dspace.inc.saude.gov.br/handle/123456789/687
dc.language.isoen
dc.publisherThorax
dc.subjectAdulten
dc.subjectAntibiotics, Antitubercular / administration & dosageen
dc.subjectAntibiotics, Antitubercular / adverse effectsen
dc.subjectAntibiotics, Antitubercular / economics*en
dc.subjectBrazilen
dc.subjectCanadaen
dc.subjectCost-Benefit Analysisen
dc.subjectDrug Administration Scheduleen
dc.subjectDrug Costs / statistics & numerical dataen
dc.subjectHealth Care Costs / statistics & numerical data*en
dc.subjectHealth Services / statistics & numerical dataen
dc.subjectHumansen
dc.subjectIsoniazid / administration & dosageen
dc.subjectIsoniazid / adverse effectsen
dc.subjectIsoniazid / economicsen
dc.subjectLatent Tuberculosis / drug therapy*en
dc.subjectLatent Tuberculosis / economics*en
dc.subjectRifampin / administration & dosageen
dc.subjectRifampin / adverse effectsen
dc.subjectRifampin / economics*en
dc.subjectSaudi Arabiaen
dc.titleImpact of treatment completion, intolerance and adverse events on health system costs in a randomised trial of 4 months rifampin or 9 months isoniazid for latent TB
dc.typeArticle
Arquivos
Original bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.alt
Nome:
Aspler A et al_Thorax.pdf
Tamanho:
84.63 KB
Formato:
Adobe Portable Document Format
Descrição:
Baixar
License bundle
Agora exibindo 1 - 1 de 1
thumbnail.default.placeholder
Nome:
license.txt
Tamanho:
1.71 KB
Formato:
Item-specific license agreed to upon submission
Descrição:
Baixar
Coleções
Produção Docente